FLUIDIGM CORPORATION (NASDAQ:FLDM) Files An 8-K Entry into a Material Definitive AgreementItem 9.01
On August 2, 2017, Fluidigm Corporation (the “Company”) and ARE-SAN FRANCISCO NO. 17, LLC entered into an amendment (the “Amendment”) to the lease agreement dated as of September 14, 2010, as amended (the “Lease”), relating to the leaseof office and laboratory space at the Company’s headquarters located at 7000 Shoreline Court, South San Francisco, California. The Amendment provides for the following:
| · | the reduction in the size of the premises covered under the Leaseby approximately 13,000 square feet of space (the “Surrendered Space”) effective on August 15, 2017; |
| · | reduction in the obligation of the Company to pay monthly base rent and operating expenses for the Surrendered Space as of August 15, 2017, resulting in an aggregate savings of approximately $2,000,000.00 during the remaining term of the Lease; and |
| · | commencing on January 1, 2018, payment by the Company to the landlord of a total of $203,829.31 payable in equal monthly installments over the remaining term of the Lease. |
The foregoing summary of the Amendment is not complete and is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
|
ExhibitNo. |
Description |
| 10.1 | Eighth Amendment to Lease Agreement between ARE-San Francisco No. 17, LLC and the registrant, dated August 2, 2017. |
FLUIDIGM CORP ExhibitEX-10.1 2 t1702281_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EIGHTH AMENDMENT TO LEASE THIS EIGHTH AMENDMENT TO LEASE (this “Eighth Amendment”) is made as of August 2,…To view the full exhibit click here
About FLUIDIGM CORPORATION (NASDAQ:FLDM)
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
